These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34633420)

  • 21. Listening to Provenge--what a costly cancer treatment says about future Medicare policy.
    Chambers JD; Neumann PJ
    N Engl J Med; 2011 May; 364(18):1687-9. PubMed ID: 21470004
    [No Abstract]   [Full Text] [Related]  

  • 22. Cancer research: does it deliver for the patient?
    Oldham RK
    Cancer Biother; 1994; 9(2):99-102. PubMed ID: 7812366
    [No Abstract]   [Full Text] [Related]  

  • 23. Use and coverage of novel cancer agents in managed care.
    Bailes JS
    Semin Oncol; 1994 Dec; 21(6 Suppl 14):34-7. PubMed ID: 7992098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NICE and the challenge of cancer drugs.
    Raftery J
    BMJ; 2009 Jan; 338():b67. PubMed ID: 19141502
    [No Abstract]   [Full Text] [Related]  

  • 25. 340B Drug Pricing Program Reform.
    Fong WH
    JAMA Oncol; 2016 Mar; 2(3):403. PubMed ID: 26967190
    [No Abstract]   [Full Text] [Related]  

  • 26. Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs.
    Cohen J; Malins A; Shahpurwala Z
    Health Aff (Millwood); 2013 Apr; 32(4):762-70. PubMed ID: 23569057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paying accurately for imaging services in medicare.
    Winter A; Ray N
    Health Aff (Millwood); 2008; 27(6):1479-90. PubMed ID: 18997203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 340B Drug Pricing Program Reform-Reply.
    Kantarjian H; Chapman R
    JAMA Oncol; 2016 Mar; 2(3):403-4. PubMed ID: 26967191
    [No Abstract]   [Full Text] [Related]  

  • 29. CMS Will Cover Alzheimer Drugs With Traditional FDA Approval.
    Harris E
    JAMA; 2023 Jul; 330(1):14. PubMed ID: 37314825
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implementation of the biosimilar pathway: economic and policy issues.
    Grabowski H; Long G; Mortimer R
    Seton Hall Law Rev; 2011; 41(2):511-57. PubMed ID: 21739758
    [No Abstract]   [Full Text] [Related]  

  • 32. Interpretation of surrogate endpoints in the era of the 21st Century Cures Act.
    Knopf K; Baum M; Shimp WS; Bennett CL; Faith D; Fishman ML; Hrushesky WJ
    BMJ; 2016 Dec; 355():i6286. PubMed ID: 28039123
    [No Abstract]   [Full Text] [Related]  

  • 33. Value of the 340B Drug Discount Program.
    Kantarjian H; Chapman R
    JAMA Oncol; 2015 Nov; 1(8):1029-30. PubMed ID: 26313652
    [No Abstract]   [Full Text] [Related]  

  • 34. Innovative New Drugs for Serious Nonlethal Diseases: The Cost to Develop and the Cost to Buy.
    Eaglstein WH
    JAMA Dermatol; 2016 Feb; 152(2):139-40. PubMed ID: 26606648
    [No Abstract]   [Full Text] [Related]  

  • 35. Pushback on Zaltrap's price highlights sensitive end-of-life issue.
    Dalzell MD
    Manag Care; 2012 Dec; 21(12):40-1. PubMed ID: 23304735
    [No Abstract]   [Full Text] [Related]  

  • 36. Coverage policy and use beyond the FDA-approved label.
    McGivney WT
    J Natl Compr Canc Netw; 2006 Feb; 4(2):99-101. PubMed ID: 16451768
    [No Abstract]   [Full Text] [Related]  

  • 37. Real-world evidence-What is it and does it matter for approval of drugs?
    Eaglstein WH
    J Am Acad Dermatol; 2018 Aug; 79(2):390-391. PubMed ID: 29410344
    [No Abstract]   [Full Text] [Related]  

  • 38. Early accelerated approval for highly targeted cancer drugs.
    Chabner BA
    N Engl J Med; 2011 Mar; 364(12):1087-9. PubMed ID: 21428763
    [No Abstract]   [Full Text] [Related]  

  • 39. Demand grows for early access to promising cancer drugs.
    Baldwin J
    J Natl Cancer Inst; 2002 Nov; 94(22):1668-70. PubMed ID: 12441318
    [No Abstract]   [Full Text] [Related]  

  • 40. Give a little ... get a lot.
    Haylock PJ
    Clin J Oncol Nurs; 2001; 5(1):4. PubMed ID: 11899403
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.